Hypofractionated radiotherapy with concomitant sunitinib - is there a radiosensitizing effect?
We present a case of a patient with metastatic renal cell cancer (RCC) treated with hypofractionated radiotherapy while being treated with sunitinib. He received a single dose of 8 Gy of external beam radiation to a metastatic mass of several centimeters diameter in the right lateral ribs, followed by a second identical dose. Clinically, the patient achieved a nearly complete disappearance of the mass. We discuss the possible synergy between tyrosine kinase receptor inhibitors (TKRIs) and radiotherapy and the importance of dose fractionation.
Taussky
Daniel
D
Department of Radiation Oncology, CRCHUM-Centre Hospitalier de l'Université de Montréal - Hôpital Notre-Dame, Montreal, Quebec, Canada.
Soulières
Denis
D
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000532:radiotherapy*; D018450:Disease Progression; D019583:Dose Fractionation, Radiation; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000556:secondary; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D000077210:Sunitinib
D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D011838:Radiation-Sensitizing Agents; D000077210:Sunitinib